RT Journal Article
SR Electronic
T1 A mucosal antibody response is induced by intra-muscular SARS-CoV-2 mRNA vaccination
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.08.01.21261297
DO 10.1101/2021.08.01.21261297
A1 Salma Sheikh-Mohamed
A1 Baweleta Isho
A1 Gary Y.C. Chao
A1 Michelle Zuo
A1 George R. Nahass
A1 Rachel E. Salomon-Shulman
A1 Grace Blacker
A1 Mahya Fazel-Zarandi
A1 Bhavisha Rathod
A1 Karen Colwill
A1 Alainna Jamal
A1 Zhijie Li
A1 Keelia Quin de Launay
A1 Alyson Takaoka
A1 Julia Garnham-Takaoka
A1 Christina Fahim
A1 Aimee Paterson
A1 Angel Xinliu Li
A1 Nazrana Haq
A1 Shiva Barati
A1 Lois Gilbert
A1 Karen Green
A1 Mohammad Mozafarihashjin
A1 Philip Samaan
A1 Patrick Budylowski
A1 Walter L. Siqueira
A1 Samira Mubareka
A1 Mario Ostrowski
A1 James M. Rini
A1 Olga L. Rojas
A1 Allison McGeer
A1 Irving L. Weissman
A1 Michal Caspi Tal
A1 Sharon Straus
A1 Anne-Claude Gingras
A1 Jennifer L. Gommerman
YR 2021
UL http://medrxiv.org/content/early/2021/08/19/2021.08.01.21261297.abstract
AB The first line of defense against SARS-CoV-2 is the upper respiratory tract, yet we know little about the amount, type, and kinetics of mucosal anti-Spike antibodies (Ab) in response to intramuscular (i.m.) COVID-19 vaccination. We analyzed salivary Ab against SARS-CoV-2 Spike following mRNA/mRNA and adenovirus (Ad)/mRNA regimes. While anti-Spike/RBD IgG was detected in the saliva and correlated with the systemic response, anti-Spike/RBD IgA associated with the secretory component (sIgA) was also detected, and did not necessarily correlate with serum Ab. Only modest levels of neutralizing capacity were observed in saliva at 2 weeks post-dose 2, and by 6 months, anti-Spike/RBD IgG were greatly diminished. In contrast, low levels of anti-Spike sIgA persisted up to 6 months after dose 2. Our results show that SARS-CoV-2 vaccination induces an IgG response in the saliva that decays over time and an sIgA response that does not necessarily correlate with systemic immunity.One-Sentence Summary Our study delves into how intra-muscular mRNA/mRNA or mRNA/Ad COVID-19 vaccination regimes confer immunity in the oral cavity with important implications for understanding protection against breakthrough infections in healthy vaccinated people.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by an Ontario Together province of Ontario grant to JG and ACG and a Foundation grant from the Canadian Institutes of Health Research to JG (Fund #15992). Funding for the LTCH cohort was provided through a Canada COVID-19 Immunity Task force grant (to SS, AM, MO, ACG and JG). Funding for initial development of the assays in the Gingras lab was provided through generous donations from the Royal Bank of Canada (RBC) and the Krembil Foundation to the Sinai Health System Foundation. The robotics equipment used is housed in the Network Biology Collaborative Centre at the Lunenfeld-Tanenbaum Research Institute, a facility supported by Canada Foundation for Innovation funding, by the Ontarian Government and by Genome Canada and Ontario Genomics (OGI-139).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Mount Sinai Hospital Research Ethics Board (REB) granted approval for recruiting staff in long-term care facilities located in the Greater Toronto Area for blood and saliva collection and for conducting serum ELISAs at the Lunenfeld-Tanenbaum Research Institute (study number: 20-0339-E). The University of Toronto REB granted approval for subject recruitment to collect blood and saliva samples and for conducting saliva ELISAs (study number: 23901). The University of Saskatchewan REB granted approval for saliva sample collection during the pre-COVID era (study number: BIO-USask-1579).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data will be available upon reasonable request.